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Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized by
relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough. Both
the incidence and prevalence of IPF appears to be increasing, with little impact on its dismal
3-year median survival, despite two decades of clinical trials. Increasingly recognized are the
serious associated comorbid illnesses, including pulmonary hypertension, chronic obstructive
pulmonary disease, gastroesophageal reflux disease, obstructive sleep apnea, obesity, lung
cancer, and depression that further contribute to the substantial rise in the use of IPF-
related healthcare resources. At present, lung transplantation remains the sole viable treat-
ment for the few who qualify. Pharmacologic interventions targeting lung function and survival
have remained largely disappointing, and very few investigations have specifically targeted co-
morbid conditions, symptoms, quality-of-life, and healthcare resource utilization. In reviewing
the burden of illness associated with IPF, including the epidemiology, comorbidities, quality-
of-life and the physical, psychosocial, and economic costs of this devastating disease, we hope
to highlight some of the unmet medical needs associated with IPF, and encourage both public
support and further investigations into these and other patient-centered outcomes and not
just that of survival and lung function.
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Idiopathic pulmonary fibrosis (IPF) is the most common and
severe form of the idiopathic interstitial pneumonias and is
an exclusionary diagnosis considered in the appropriate
clinical context when there is evidence of physiologic
impairment in gas exchange or lung function and confir-
mation of usual interstitial pneumonia (UIP). IPF is a pro-
gressive disease with a survival rate as dismal as lung
cancer [1], but with a variable often unpredictable course
in the individual. Patients universally develop dyspnea
from progressive ventilatory restriction and hypoxia and
often carry multiple comorbid conditions, including pul-
monary hypertension (PH), gastroesophageal reflux disease
(GERD), obesity, lung cancer, and emphysema [2,3]. The
incidence of IPF appears to be increasing and is due in part
to the aging population, increased awareness of IPF among
patients and clinicians, and the improved ability to di-
agnose IPF due to advances in CT imaging [4]. Neverthe-
less, and despite more than three decades of clinical
research, effective pharmacotherapies remain to be iden-
tified [2], with no approved drugs available in the United
States [5]. Lung transplantation is an option for those
eligible but with a still dismal median post-transplant sur-
vival of 4.5 years [6].
Most IPF research has focused predominantly on lung
function (forced vital capacity, FVC) and mortality [2,7,8],
or other biomarkers that track these outcomes. However,
specific efficacy endpoints, including measures important
to the patient (e.g. health-related quality of life [HRQOL]
or patient reported outcomes [PRO]), have been of little
interest in clinical trials. Given the growing number of older
adults and overall burden of illness associated with IPF, the
need for effective and well-tolerated therapies derived
from an expanded set of clinical-trial endpoints has become
increasingly more relevant and urgent [2,3,9]. Similarly, at
the public health level, the study of healthcare utilization
in IPF has not received the same attention as other chronicpulmonary diseases, such as asthma and chronic obstructive
pulmonary disorder (COPD). Although several recent pub-
lications have reviewed the burden of IPF with respect to
comorbidities, HRQOL, and economic costs, systematic in-
vestigations remain lacking [3,10e18].
In this paper, we review and summarize the current
state of evidence on the epidemiology, symptom burden,
and resource burden of IPF. In so doing, we hope to present
a case for the allocation of additional research and clinical
resources to meet the comprehensive medical needs of
patients with IPF, emphasizing the importance of incorpo-
rating additional outcome measures for specific symptoms,
comorbidities, and HRQOL/PRO associated with IPF. We
also aim to better understand healthcare resource utiliza-
tion and processes in the setting of IPF that may allow us to
more efficiently alter the natural course of this disease.
Methods
This paper is based on Medline literature searches that
were undertaken to identify relevant articles published in
English since 1990. Search terms included idiopathic pul-
monary fibrosis or interstitial lung disease in combination
with burden, cost, quality of life, healthcare utilization,
comorbidities, and epidemiology. Reference lists from
selected original research articles were also reviewed;
relevant studies and reviews identified therein were
incorporated in the present analysis.
Epidemiology of IPF
The prevalence of IPF in the United States (US) range from
14.0e27.9 and 42.7e63.0 cases per 100,000 people (using
narrow- and broad-case definitions, respectively), or from
between 90,000 and 190,000 patients, a range similar to
that reported in Europe: 1.25e23.4 cases per 100,000
[2,3,10,19e21]. Among the elderly (>65 years old), 1 per
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study suggest a prevalence of 2.9 cases per 100,000 people
[10,22]. The annual incidence ranges from 6.8e8.8 and
16.3e17.4 per 100,000 people (narrow- and broad-case
definitions, respectively) in the US, and 0.22e7.4 per
100,000 in Europe (Table 1) [20,21]. Although differences in
diagnostic criteria, case definition, study population, and
study design contribute to the observed variability in the
findings, the evidence suggests on whole that both the
prevalence and incidence of IPF are increasing [10,23,24].Morbidity and mortality
Mortality in IPF remains high with a median survival of 3e5
years from diagnosis [12,25e29]. Due to an aging popula-
tion and the apparent increase in the prevalence and
incidence of IPF, the overall mortality rate due to IPF ap-
pears to have increased over the past 20 years [3,4,24,25].
Between 1979 and 1991, mortality rates for IPF in Ameri-
cans increased slightly from 48.6 to 50.9 deaths per 100,000
men, and 21.4 to 27.2 in women [30]. Applying the most
rigorous definition of IPF, a more recent US study from 2007
reported mortality rates of 61.2 and 54.5 deaths per
100,000 men and women, respectively [4]. RespiratoryTable 1 Prevalence and incidence of IPF.
1st Author Country,
study period
Methods and case definiti
North America
Fernandez
Perez
US, 1997‒2005 Olmsted County Historica
cohort (2005)
Narrow case definitiona
Broad case definitionb
Raghu US, 1996‒2000 Healthcare claims
database (2000)
Narrow case definitionc
Broad case definitiond
Europe
Thomeer Belgium, 1992‒6 Population-based ILD regi
20 centers; biopsy-proven
identified as IPF
Von Plessen Norway, 1984‒98 IPF cases identified based
physician
diagnoses using ICD-8 and
ICD-9 codes
Navaratham UK, 2000‒9 IPF cases identified from
primary care
data and death records
using ICD codes
a Usual interstitial pneumonia (UIP) on surgical lung biopsy specimen
(HRCT).
b UIP on surgical lung biopsy specimen or definite or possible UIP pa
c Metcriteria for broad case definition plus 1 medical claim with pr
or computed tomography of thorax on or before date of last medical
d Age 18 y, 1 medical claim with diagnosis code for IPF, no med
medical claim with diagnosis code for IPF.
e Incidence and prevalence of hospitalized IPF. ICD, International Cfailure is the most common cause of death (w60%) [4,31],
most commonly due to acute exacerbation of IPF (29%),
pneumonia (15%), and chronically progressive IPF (12%)
[31]. A significant number of IPF deaths are also related to
comorbidities such as cardiovascular disease (57%), cancer
(10%), infection (6e10%), pulmonary embolism (2e3%), and
chronic renal or liver disease (10e21%) [31,32].
Acute exacerbation (AE-IPF), which occurs in up to 20%
of IPF patients within 3 years of their diagnosis [2,33], is
often devastating with a hospital mortality rate of at least
50% [33e35]. AE-IPF is unpredictable and can occur even
with mild baseline physiological impairment [33,36,37]. It is
characterized radiologically by ground glass infiltrates
superimposed on a UIP pattern, paralleling the histologic
findings of diffuse alveolar damage on the background UIP
[2,38e42]. No clear etiology has been identified, although
infection, aspiration, and alveolar hemorrhage have been
implicated [43e45]. Even when patients survive the acute
hospitalization, the median survival time is only 4.2e15.5
months [33,34]. If respiratory failure ensues, mechanical
ventilation is rarely successful, and should be used judi-
ciously [2,46e53]. One study suggested that noninvasive
positive pressure ventilation is preferable, with “only” 74%
associated mortality, and could be appropriate for pallia-
tive use in relieving dyspnea to select patients. Theseon IPF Prevalence/100,000
population (95% CI)
IPF Incidence/100,000
population (95% CI)
l 27.9 (10.4e45.4)
63.0 (36.4e89.6)
8.8 (5.3e12.4)
17.4 (12.4e22.4)
14.0
42.7
6.8
16.3
stry in
UIP
1.25 0.22
on 23.4 (14.9‒33.0)e 4.3e
N/A 7.4 (7.1e7.8)
or definite UIP pattern on high-resolution computed tomography
ttern on HRCT.
ocedure code for surgical lung biopsy, transbronchial lung biopsy,
claim with diagnosis code for IPF.
ical claims with diagnosis code for other ILD on or after date of
lassification of Diseases. Adapted from Nalysynk 2012 [10].
958 A.S. Lee et al.findings led to an international consensus panel recom-
mending that most patients with IPF should not receive
mechanical ventilation [2]. Only rarely, following consul-
tation with the patient and caregivers about the goals of
care, should this option be used. Mechanical ventilation
may, however, be a useful bridge to lung transplantation,
provided the transplantation can be performed shortly
thereafter [53]. Although these data clearly demonstrate
the need for more effective therapies to reduce mortality,
further elucidation of the mechanisms of acute exacerba-
tions, along with better understanding of the risks (beyond
lung-function parameters) and the role of adjunct therapies
in the acute setting, are required.Clinical endpoints
In IPF, interventional studies have typically used lung
function (e.g. FVC) and mortality as endpoints. As in
contemporary COPD and pulmonary arterial hypertension
(PAH) studies, future investigations of potential IPF thera-
pies could assess comprehensive PRO and HRQOL outcomes
(targeting patients’ physical, emotional, and social func-
tioning) as core and even primary endpoints, particularly if
it appears that affecting mortality and lung function in a
significant manner is unlikely. There are several reasons
why the development and validation of appropriate PROs
and symptom endpoints could improve the utility of future
studies [54]. First, effective therapies to reverse the pro-
gressive respiratory failure or high mortality in IPF simply
are not yet available. Second, traditional lung-function
markers do not track with some important aspects of
function and QOL. Third, the use of symptom-based end-
points could clarify IPF management strategies by identi-
fying interventions that might not have otherwise been
considered when looking at traditional outcomes. For
example, the effects of pulmonary rehabilitation, oxygen
compliance and delivery, lung-cancer management, coro-
nary screening, and GERD evaluation and treatment on
patient disability and impairment need further elucidation.
Although the findings are not consistent [55,56], several
recent studies have provided valuable information gener-
ated from exploratory or secondary analyses, suggesting
that proposed pharmacological interventions may have
positive effects on HRQOL, if not on lung function or sur-
vival [57e61]. For instance, although FVC appeared to track
with QOL in the etanercept study for IPF [60], only 25% of
HRQOL was found to be attributable to lung capacity. In
addition, two other important studies have demonstrated
positive effects on QOL outcomes. In the BUILD-1 (Bosentan
Use in Interstitial Lung Disease) trial of 154 patients with
mild-to-moderate IPF, those receiving bosentan showed a
nonsignificant, but favorable, improvement in Short Form-
36 Health survey (SF-36), compared with placebo patients
(42.4% vs 28.4%; P Z 0.08) [57,58]. Unfortunately, the
follow-up investigation (BUILD-3) was unable to replicate
this secondary-endpoint result. The investigators plausibly
proposed that the null finding probably reflected the milder
IPF population chosen for the latter study [55]. The Sil-
denafil Trial of Exercise Performance in Idiopathic Pulmo-
nary Fibrosis (STEP-IPF) also was a negative study for the
primary outcome; however, there were statistically small,but clinically relevant, differences favoring sildenafil on
the St. George’s Respiratory Questionnaire (SGRQ) and the
SF-36 [59], particularly in the subset with right-ventricular
dysfunction or right-ventricular hypertrophy [56]. Similarly,
lung transplantation, which is the only therapy thought to
improve survival [62], also appears to have net benefits in
QOL [63]. However, unlike transplantation, the pharmaco-
logic therapies are considered negative studies, partially
because they were targeted as secondary endpoints and
were not a principal focus of the trials.
To further advance clinical trials with these important
outcomes in mind, a number of standardized instruments
have been validated to assess HRQOL, though none are well
suited to the specific physiologic and HRQOL dimensions of
IPF. Several studies have found that the SF-36 and SGRQ
show strong correlation between physical impairment (as
measured by the 6-min walk test and total lung capacity
score) and disease severity, clinical symptoms, and func-
tional disability in patients with IPF [17,18,60,64e66].
Other research strongly suggests, however, that the
currently available measures cannot adequately assess the
primary domains of HRQOL that affect the lives of these
patients, including overall symptom burden, treatment,
sleep, exhaustion, forethought, employment and finances,
dependence, family, sexual relations, mental and spiritual
well-being, and social participation [54,67,68]. Under-
standing the impact of these physical, emotional, psycho-
logical, and social factors are essential to determining the
health status of IPF patients and developing therapies to
improve them. Some IPF-specific tools are being developed
and validated, including the IPF-ATAQ [69], but broadening
these instruments to include other measures of PROs, QOL,
functional status, and symptoms should be explored [54].
Comorbidities
A number of comorbidities are associated with IPF,
including PH, emphysema, diabetes, lung cancer, GERD,
depression, obstructive sleep apnea (OSA), and cardiovas-
cular disease [3,14e16,70e75]. Most IPF patients will have
at least one of these secondary complications, which will
contribute to their impairment and disability, and further
compromise their QOL and survival (Table 2). As a conse-
quence, the overall burden of illness for patients with IPF,
including healthcare resource utilization and direct medical
costs, can be significant.
Pulmonary hypertension
In almost any chronic lung disease, including IPF, PH can
complicate the primary disorder and worsen prognosis.
According to US claims data, 2.7% (nZ 249) of IPF patients
had PH, compared with 0.2% (n Z 16) of non-IPF controls
resulting in a relative risk for PH of 15.56 (95% CI
9.39e25.80) (Table 2) [3]. In a review of 2225 IPF patients
entered into the US lung-transplant registry, right-heart
catheterization data suggests a substantially higher preva-
lence of PH e up to 46.1%. Patients had a mean pulmonary
artery pressure (mPAP) 25 mmHg, with 9% of those clas-
sified as severe (mPAP >40 mmHg) [74]. A multivariate
analysis in this cohort revealed that the need for oxygen,
Table 2 Prevalence of selected comorbidities.
Comorbiditiesa IPF (n Z 9286) Control (nZ9286) Relative Risk (95% CI)
n (%) n (%)
Pulmonary infection 2818 (30.3) 672 (7.2) 4.20 3.86e4.57)*
Coronary artery disease (excluding MI) 2361 (25.4) 1268 (13.7) 1.86 (1.74e1.99)*
Diabetes 2329 (25.1) 1737 (18.7) 1.34 (1.26e1.43)*
Heart failure 1880 (20.2) 491 (5.3) 3.83 (3.47e4.23)*
Chronic bronchitis 1126 (12.1) 217 (2.3) 5.19 (4.50e6.02)*
Atrial fibrillation 1110 (12.0) 571 (6.1) 1.94 (1.76e2.15)*
Fatigue 835 (9.0) 412 (4.4) 2.03 (1.80e2.18)*
Cerebrovascular disease 817 (8.8) 598 (6.4) 1.37 (1.23e1.52)*
Asthma 792 (8.5) 203 (2.2) 3.90 (3.36e4.58)*
Emphysema 740 (8.0) 104 (1.1) 7.11 (5.79e8.73)*
Gastroesophageal reflux disease 666 (7.2) 275 (3.0) 2.42 (2.10e2.79)*
Sleep apnea 551 (5.9) 151 (1.6) 3.65 (3.05e4.37)*
Depression 319 (3.4) 228 (2.5) 1.40 (1.18e1.66)*
Myocardial infarction 298 (3.2) 140 (1.5) 2.13 (1.74e2.60)*
Lung cancer 283 (3.0) 100 (1.1) 2.83 (2.25e3.55)*
Pulmonary embolism 251 (2.7) 36 (0.4) 6.97 (4.92e9.89)*
Pulmonary hypertension 249 (2.7) 16 (0.2) 15.56 (9.39e25.80)*
Rib fracture 61 (0.7) 24 (0.3) 2.54 (1.59e4.08)*
Obesity 60 (0.6) 27 (0.3) 2.22 (1.41e3.50)*
Deep vein thrombosis 50 (0.5) 29 (0.3) 1.72 (1.09e2.72)**
*P < 0.0001; **P < 0.02.
Reprinted from Collard 2012 [3].
a determined from claims recorded during the 6 months before the index date. CI, confidence interval; IPF, idiopathic pulmonary
fibrosis; MI, myocardial infarction.
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capnea were independent risk factors for PH. Most series
have confirmed a higher mortality when PH is present in IPF
patients, with the rate proportionate to the PH severity
[76,77]. In one series, the median survival was 4.8 years
when there was no significant PH (systolic PAP 35 mmHg)
vs 0.7 years with more severe PH (sPAP>50 mmH) [77].
Notably, the association between the degree of hypoxia,
fibrosis, and ventilatory impairment is not always well
correlated with PH severity [76,78], suggesting a separate
superimposed vasculopathy may be an additional or
concomitant mechanism for this complication in IPF pa-
tients [79]. However, clinical trials targeting PH in IPF have
thus far been disappointing [55,59], failing to show any
substantial benefits in primary outcomes of survival or
functional status. Success in this area may be contingent on
being able to better identify those with a separate “vas-
culopathy” of PH or with novel agents that are less likely to
impair gas-exchange.
Lung cancer
Most epidemiologic investigations [32,36,75,80e88] report
an increased incidence of lung cancer among IPF patients,
relative to controls, with one study finding an incidence
ratio relative to controls of 1.51 (95% CI 1.20e1.90) [81].
Overall, the estimated prevalence of lung cancer among IPF
patients ranges from 20.4% to 31.3% [83,84]. Pulmonary
fibrosis appears to be a risk factor for lung cancer inde-
pendent of smoking, a shared risk factor for the develop-
ment of both diseases [87]. The aberrant fibrotic process isbelieved to be the potential nidus for “scar” carcinoma
formation, and this proposed mechanism is consistent with
the finding of squamous cell carcinoma as the common
histology in IPF in some reports [80,88]. Nevertheless, the
majority (56%) of tumors were not found in fibrotic areas,
as might be expected of “scar” carcinomas [75]. Indepen-
dent predictors of lung cancer in IPF patients in one series
out of Korea included older age 60 years (OR 2.41, 95% CI
1.10e5.25), smoking (OR 2.71, 95% CI 1.91e6.21), and male
gender (11.04, 95% CI 2.46e49.60). Following a diagnosis of
lung cancer, the risks of both diagnostic and treatment in-
terventions are magnified for IPF patients [85,89], and the
prognosis remains uncertain.
Combined pulmonary fibrosis and emphysema
Although emphysema and IPF are distinct clinical, radio-
logic, pathologic, and even functionally opposing entities,
they may co-exist in variable degrees of severity in 8e29%
[90,91] of patients with IPF. Several series [16,92e94] have
demonstrated the characteristic upper-zone emphysema
coexisting with predominantly basilar fibrosis, which
typically exhibits the UIP pattern seen in IPF [90]. Notably,
most reports on combined pulmonary fibrosis and emphy-
sema (CPFE) have not always rigorously tried to separate
UIP with emphysema from other non-UIP causes of ILD.
The mean age in most of these reports is typically in the
60s and are predominantly males with a smoking history, a
finding that highlights this important shared risk factor
[16,91,95]. All patients will have exertional dyspnea, but
clubbing (43%) and crackles (67%) are not universal [16].
960 A.S. Lee et al.Because of opposing ventilatory defects, CPFE is associ-
ated with a higher TLC and FVC, but a lower FEV1/FVC
ratio and diffusing capacity (DLCO), compared with IPF
[91]. As a result, some may have minimal-to-no spiro-
metric or lung-volume abnormalities, and the presence of
an impaired DLCO or hypoxia may be the only abnormal
findings. The rate of decline in FVC is reduced in some
reports [96], possibly due to these opposing factors, raising
some concern on whether FVC is an appropriate outcome
measure for IPF when emphysema is not carefully
excluded.
Patients with CPFE also have a higher frequency of both
PH and lung cancer, compared with patients with IPF alone
[16]. PH is more common (47%) and more severe in patients
with CPFE, compared with those having IPF alone [16,91],
and is associated with poorer survival, relative to those
without PH: 87.5% at 2 years and 54.6% at 5 years [16]. Lung
cancer also complicates CPFE in up to 46.8%, a significantly
higher rate than is reported in COPD or IPF alone [95,97].
Given the clinical, physiologic, and prognostic differences,
CPFE may be a distinct entity or a subtype of IPF. Further
research will be necessary to clarify the nature of the
relationship and how they should be considered in primary
outcomes trials in IPF.Gastroesophageal reflux disease and aspiration
A number of series have established the increased preva-
lence of GERD in IPF, compared with non-IPF patients and
other chronic lung diseases. In two such US series, the
prevalence was reported to be as high as 87e94% following
24-h esophageal pH testing, although 25e53% of cases were
asymptomatic of classic reflux symptoms [20,98]. The
increased prevalence of GERD and the high degree of
asymptomatic patients is found in other countries as well,
although to a lesser extent [65,99,100]. In both US- and UK-
based studies [3,71], extrapolated data suggest the relative
risk of having GERD or taking anti-ulcer medications in IPF
patients is more than 2-fold higher than in controls (Table
2). Although the degree of reflux has not correlated well
with physiologic impairment on lung-function testing [20], a
more recent series of 40 consecutive IPF patients identified
a strong and significant correlation (r2 Z 0.63) between
fibrosis severity (as measured by HRCT imaging) and reflux
severity (as measured by impedance-pH monitoring) [101].
Further highlighting the potential clinical relevance of
GERD in IPF is a large retrospective analysis showing that
GERD therapy was associated with improved survival [102].
These findings, along with evidence of esophageal dys-
motility [99] and the prevalence of proximal reflux [20,98],
have led to the hypothesis that IPF patients may be
“silently” aspirating or “micro-aspirating”. Clinically occult
aspiration has been observed and pathologically confirmed
in other clinical contexts outside of IPF [103,104], and with
the advent of gastric-to-pulmonary aspiration biomarkers,
such as bile and pepsin in bronchoalveolar lavage (BAL)
fluid, an increasing number of reports propose that aspi-
ration may also be the link between GERD and IPF. Whether
GERD and aspiration is causal to IPF or is a consequence of
IPF, and whether we can intervene at this level, remain
uncertain.Obstructive sleep apnea
Occurring in about 20% of older adults in the general pop-
ulation [105], OSA is associated with multiple comorbid-
ities, include hypertension, PH, increased insulin
resistance, upregulation of inflammatory cytokines, and
possibly GERD [106e108]. Any ILD may be associated with
disturbed sleep, nocturnal desaturations, nocturnal cough,
and OSA [109,110]. More recent studies have confirmed a
surprisingly high prevalence of OSA specifically in IPF
[26,110e112]. In an outpatient sample of stable IPF pa-
tients (n Z 50), OSA was confirmed by polysomnography in
88% [26]. Of those, 20% were mild (apneaehypopnea index
[AHI] 5e15 events per hour), and 68% were moderate-to-
severe (AHI >15/hour). Similarly, in a small study of
newly diagnosed IPF patients, OSA (AHI 5/hour) was pre-
sent in the majority (59%) [112]. This study noted that the
AHI inversely correlated with the TLC, particularly during
the rapid-eye-movement phase of sleep. Interestingly,
most studies do not always show a strong correlation be-
tween the body mass index (BMI) and the AHI. Although the
precise mechanistic relationship between OSA and IPF
needs further clarification, evidence is now emerging that
OSA might cause subclinical lung injury [113,114] through
alveolar stretch [115], oxidative stress, and micro-
aspiration [116]. Given that OSA is common and probably
under-recognized in IPF [26], clinicians should consider
screening for this important comorbidity that may affect
the patient’s QOL, even as further investigations are pur-
sued to identify mechanisms and best therapeutic
approaches.Cardiovascular disease
Compared with the general population, patients with IPF
have an elevated risk of cardiovascular diseases
[3,15,32,72]. Two recent investigations sought to clarify the
association and potential impact of cardiovascular disease
in patients with IPF. In a UK study comparing 920 incident
IPF patients (mean age 71 years; 62% men) with matched
controls (n Z 3593), patients with IPF had significantly
more acute coronary syndromes (ACS), with an odds ratio
(OR) of 1.53 (95% CI 1.15e2.03), as well as angina (OR 1.84;
95% CI 1.48e2.29), and deep-vein thrombosis (DVT) (OR
1.98; 95% CI 1.13e3.48) [15]. Following the diagnosis of IPF,
the risks further increased, with a relative risk (RR) of 3.14
(95% CI 2.02e4.87) for subsequent ACS and an RR of 3.39
(95% CI 1.57e7.28) for subsequent DVT, independent of
smoking history, age, or sex. Similarly, in a US prospective
study of 73 patients with IPF and 56 with COPD, coronary
artery disease (CAD) was more prevalent in IPF (65.8% vs
46.1%; P < 0.03), with 28.8% requiring intervention or
having a major vessel lesion >50% [72]. Unsuspected
advanced CAD was also more frequent in IPF than in COPD
(18% vs 10.9%; P < 0.004), even though cigarette smoking
was greater in the COPD group. Patients with IPF and sig-
nificant CAD have a significantly shorter median survival
(w572 days) from the time of left-heart catheterization
(Fig. 1) [14], a finding consistent with prior observations
that ischemic heart disease is the fourth (9.5%) most com-
mon cause of death in patients with IPF, following
Figure 1 Patients with IPF and significant coronary artery
disease (CAD) have a shorter median survival compared to
patients with non-significant or no CAD. Reprinted with
permission from Nathan 2010 [14].
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noma [32]. In an autopsy series of IPF patients, myocardial
infarction was the immediate cause of death in 7%, while
ischemic heart disease contributed to the patient’s death in
31% [31]. These findings highlight the strength of the as-
sociation between IPF and CAD, as well as its clinical
importance. Although the link between IPF and thrombosis-
related clinical events offers a theoretical rationale for the
use of anticoagulation therapy, a recent placebo-controlled
study of warfarin in patients with IPF was terminated early
due to lack of benefit and an increased mortality [117].
In summary, cardiovascular comorbidities are common in
IPF (Table 1) and appear to be more common than in other
smoking-related chronic lung diseases. The precise mech-
anism for this is unclear, although local lung injury and
repair may play a role by up-regulating protease inhibitors,
increasing coagulability, suppressing fibrinolysis, and pro-
moting atherosclerosis. These actions could potentiate
thrombotic events in non-pulmonary vessels [72]. Super-
imposed hypoxia with progressive fibrotic lung disease also
has the potential to unmask or exacerbate underlying
ischemic disease as another mechanism. Thus, screening
for and managing any identified coronary risks should be
aggressively pursued, with the caveat that the empiric use
of statins remains somewhat controversial in IPF [118].
Depression
Clinically important depression is highly prevalent in pa-
tients with ILD including IPF, affecting 23e27% of patients
with ILD [12,119]. One study found that, while Type D
(distressed) personality is no more prevalent in IPF patients
than in the general population, depressive symptoms may
help explain QOL impairment and fatigue [120]. In another
study of 52 patients with ILD, dyspnea was associated with
measures of physical impairment (4-m walk time) and
physiologic impairment (FVC and DLCO), but also was
independently correlated with depression [12]. As with
COPD patients, depression should be considered in IPF pa-
tients, and if identified, potentially treated. However, fewstudies have investigated this important comorbidity and
tried to determine whether its treatment could successfully
impact dyspnea, QOL, and functional status.
Symptoms, impairment, and quality of life
Dyspnea and cough are hallmark symptoms of IPF, and both
appear to have important effects not only on QOL but also
on survival [12,121e123]. QOL is further worsened as daily
activities become restricted and patients grow increasingly
oxygen dependent, debilitated, and dependent on others
[12,13,17,18,64,123,124]. In the absence of treatments
that can reverse fibrosis or have meaningful effects on
respiratory impairment, future investigations should target
patient-centered or patient-reported outcomes (PRO) and
HRQOL factors, both as trial endpoints and important
measures of the effectiveness of therapeutic interventions
[54].
Dyspnea
Dyspnea is the primary symptom burden in IPF, affecting
over 90% of patients at the time of diagnosis [125]. Although
often overlooked as a symptom, rather than as a measure or
outcome, there are significant repercussions to having
dyspnea. When dyspnea was scored on the simple modified
Medical Research Council scale, it proved in a multivariate
analysis of 93 IPF patients to be the strongest predictor of
survival (hazard ratio 2.18), irrespective of pulmonary
physiology (Fig. 2) [123]. Thus, dyspnea is not only an
important contributor to morbidity and worse HRQOL, but it
is also an important predictor of mortality
[18,67,68,123,126,127]. This finding provides further evi-
dence for the recommendation that the formal evaluation
of dyspnea, using a validated instrument, should be routine
in the management of IPF. In addition to having re-
percussions on survival, dyspnea (as well as cough) corre-
lates with physical impairment, diminished general health,
decreased function, reduced energy level, and less inde-
pendence; these difficulties compromise the patient’s
ability to travel, stay socially engaged, and enjoy sexual
relations [67,68]. As activities of daily living become harder
to perform, patients and caregivers must commonly reor-
ganize and restructure their lives, sometimes with signifi-
cant psychosocial [68] and economic consequences.
Because hypoxia is not the sole mechanism for dyspnea in
IPF [128], other modalities, including pulmonary rehabili-
tation (PR), may be beneficial and should be further
investigated [61]. Indeed, emerging evidence suggests that
PR may offer significant short- and long-term improvement
in functional exercise capacity, HRQOL, and degree of
perceived dyspnea [129,130]. For instance, one study of 54
ILD patients (22 with IPF) reported that the majority of
subjects improve in their QOL (51%), dyspnea (65%), and
depression (52%) immediately following PR. Moreover, im-
provements in QOL, dyspnea, and physical activity were
sustained at 6 months [130]. While therapies that reduce
dyspnea should have a positive effect on QOL and impair-
ment, they may also correlate with improved survival, in-
dependent of lung physiology. Regardless, both clinicians
and researchers alike should target dyspnea as an
Figure 2 Dyspnea predicts survival, as shown in
KaplaneMeier survival curves based on a) the modified Medical
Research Council (MRC) score and b) presence of desaturation
(lowest Sp,O2, 88%) during the 6-min walk test. Reprinted with
permission from Nishiyama 2010 [123].
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that will impact underlying fibrotic lung disease and
survival.
Cough
Although the pathogenesis of cough in IPF is not fully un-
derstood, limited evidence suggests that there is an
increased cough-reflex sensitivity from upregulation of in-
flammatory mediators at the level of the alveoli and pe-
ripheral airways [131e133]. Upwards of 73e86% of IPF
patients will experience frequent dry, nonproductive and
hacking coughs [123,134,135]. Cough frequency can be se-
vere, and when measured objectively by an acoustic
monitor, it will strongly correlate (r2 w0.64) with both
subjective cough severity (visual analogue scales) as well as
QOL (Leicester Cough Questionnaire) [122]. Furthermore,
cough also appears to be an independent predictor of dis-
ease progression and time-to-lung transplantation or death,
highlighting the importance of using cough as a PRO in IPF[136]. Studies have already started to target cough in ILD,
including IPF, as an outcome that can be targeted to
improve a patient’s QOL [137e140]. The largest such study
investigated thalidomide in 98 IPF patients over 24 weeks
and found a significant improvement in the Cough Quality of
Life Questionnaire, as well as in cough severity [137].
Although there were significant issues of tolerability, such
studies have provided encouraging data that this important
patient-centered symptom, and contributor of worsened
QOL and impairment, can be favorably influenced.
Palliative care
IPF is a progressive debilitating disease, with no hope of a
cure on the horizon. However, palliative care has been
shown to enhance HRQOL by focusing on the physical,
psychosocial, and spiritual needs (Table 3) of the patient,
and may also help to facilitate end-of-life discussions for
patients and caregivers [141,142]. Most private and public
insurers will support hospice care with IPF as the admitting
indication, and it can be provided both in the outpatient or
inpatient setting. Opioids and possibly steroids may be used
for palliation of cough and dyspnea but complete symptom
control can remain challenging [2] while causing untoward
effects. Although there is a stigma associated with hospice
or palliative care, it is noteworthy that in other terminal
diseases, QOL can be successfully improved without having
a significant effect e or in the case of lung cancer, a
favorable effect e on survival [143]. IPF is terminal diag-
nosis without a known cure; thus, there is a need for formal
investigations on different palliative strategies and their
outcomes. For now, clinicians should proactively discuss
these approaches as a therapeutic option in the manage-
ment of patients affected by advanced IPF.
Healthcare utilization
The limited data available investigating the burden of IPF
on our healthcare system demonstrate that healthcare
resource utilization and costs are high and likely to increase
in the future. A retrospective review of US claims database
showed that between 2001 and 2008, the total direct cost
for patients with IPF was $26,000/person-year and the in-
cremental cost over control subjects was $12,124 [3]. As a
comparison, the direct treatment cost of breast cancer was
w$20,000/person-year [144]. The all-cause hospital
admission rate (0.5/person-year) and outpatient visit rate
(28/person-year) were both approximately double that of
matched control subjects. Furthermore, hospital admission
rates are increasing [145] and associated with an inpatient
mortality 3-fold higher than controls [3]. Researchers in the
UK reported that the number of hospital admissions for IPF
between 1998 and 2010 grew at an annual rate of w5%
(from 5524 to 9525 patients), with the highest rate of
growth occurring in older men [145]. The mean age at the
time of admission increased from 66 to 71 years, although
the length of stay decreased by 2.1 days during this time
frame. Possible reasons for the decline in hospital days
include cost pressures for early discharge, increased
emphasis on the provision of early specialty care and access
to home oxygen, and the recognition that mechanical
Table 3 World Health Organization definition of palliative care for adults.
Palliative care for adults in an approach that improves the quality of life of patients and their families facing the problems
associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and
impeccable assessment and treatment of pain and other problems, including physical, psychosocial, and spiritual issues.
Palliative care:
 Provides relief from pain and other distressing symptoms
 Affirms life and regards dying as a normal process
 Intends neither to hasten nor postpone death
 Integrates the psychological and spiritual aspects of patient care
 Offers a support system to help patients live as actively as possible until death
 Offers a support system to help the family cope during the patient’s illness and with their own bereavement
 Uses a team approach to address the needs of patients and their families, including bereavement counseling if indicated
 Will enhance quality of life, and may also positively influence the course of the illness
 Is applicable early in the course of illness, in conjunction with other therapies that are intended to prolong life, such as
chemotherapy or radiation therapy, and includes those investigations needed to better understand and manage distressing
clinical complications
Reprinted from Lanken 2008 [142].
The burden of idiopathic fibrosis 963ventilation may do little to improve prognosis, particularly
in the context of AE-IPF [47,52,53]. Similarly, as previously
suggested, it is unclear whether palliative care as a ther-
apeutic option may have important beneficial effects on
both patient-centered outcomes and healthcare resource
utilization. As diagnostic criteria has become more refined
and accurate, and as potentially effective therapies start to
hopefully emerge, attention should be given to healthcare
resource utilization and healthcare processes to improve
the outcomes of our patients without unduly straining our
increasingly fragile healthcare system.
While healthcare utilization for IPF is rising, this devas-
tating disease continues to remain surprisingly underfunded
and underexplored. Described more than 50 years ago, we
have yet to understand the exact etiology of IPF, let alone
identify an effective therapy. Although IPF is 5 times more
common than cystic fibrosis (CF) or amyotrophic lateral
sclerosis (ALS), it receives a fraction of the research fund-
ing ($18 million for IPF vs $85 for CF and $48 million for ALS)
[146]. This may in part be due to a lack of awareness and
also perhaps because IPF predominantly affects our elderly.
As the prevalence of IPF appears to be rising along with an
increasing burden on our healthcare system, a substantial
increase in public awareness and research funding will be
necessary to address the unmet needs and reduce the
clinical and economic burden of this still incurable illness.
Conclusion
In summary, the burden of illness due to IPF is significant
and goes beyond ventilatory limitations and survival. Prior
to death, IPF patients suffer severe dyspnea, sometimes
debilitating cough, with significant physical and functional
impairment, to the detriment of their quality-of-life.
Furthermore, IPF patients carry significant comorbidities
including PH, cardiovascular disease, and lung cancer that
worsen their QOL and survival. As the prevalence of IPF
increases with our aging population, there is an increasing
strain on healthcare resources. Further public awareness
and support is essential if we are to identify an effective
therapy. Until such a cure becomes available, futureinvestigations should focus on the role of PR and target
patient-centered outcomes, including their symptoms and
comorbidities. Addressing these in a systematic and
comprehensive fashion should have an impact on patients’
QOL, if not on survival.Conflicts of interest
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